Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2025)

NewAmsterdam Pharma's EBT Margin history spans 3 years, with the latest figure at 222165.62% for Q4 2025.

  • For Q4 2025, EBT Margin rose 22288734.0% year-over-year to 222165.62%; the TTM value through Dec 2025 reached 256.87%, up 27338.0%, while the annual FY2025 figure was 256.87%, 27338.0% up from the prior year.
  • EBT Margin for Q4 2025 was 222165.62% at NewAmsterdam Pharma, up from 20691.09% in the prior quarter.
  • Across five years, EBT Margin topped out at 222165.62% in Q4 2025 and bottomed at 20691.09% in Q3 2025.
  • The 3-year median for EBT Margin is 1024.51% (2025), against an average of 15752.51%.
  • The largest YoY upside for EBT Margin was 22288734bps in 2025 against a maximum downside of -2063390bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 2476.59% in 2023, then plummeted by -129bps to 721.71% in 2024, then soared by 30883bps to 222165.62% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EBT Margin are 222165.62% (Q4 2025), 20691.09% (Q3 2025), and 90.7% (Q2 2025).